In vivo anti-viral effect of CD4-specific monoclonal antibodies in SIVmac-infected rhesus monkeys.

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

In vivo anti-viral effect of CD4-specific monoclonal antibodies in SIVmac-infected rhesus monkeys.

Symp Nonhum Primate Models AIDS. 1993 Sep 19-22;11:abstract no. 36. Unique Identifier : AIDSLINE PRIM11/94191630
Reimann KA; Waite BC; Cate RL; Wu Y; Olson D; Letvin NL; Burkly LC; New England Regional Primate Research Center, Harvard Medical; School, Southborough, MA 01772.

Abstract: Since monoclonal antibodies (mAb) specific for CD4 are potent inhibitors of HIV and SIV replication in vitro, we explored their potential usefulness in vivo as an AIDS therapy. The anti-CD4 mAb 5A8 efficiently inhibits HIV and SIVmac replication in vitro and virus-induced cell fusion. This antibody binds to domain 2 of the CD4 molecule and inhibits virus replication at a post-virus binding step. A single 3 mg/kg intravenous administration of mAb 5A8 in normal rhesus monkeys coated all circulating and lymph node CD4 cells for 4-6 days. CD4 cells were not cleared from circulation, but rather increased in number. These animals retained normal in vitro lymphocyte proliferative responses and generated normal humoral responses. The loss of cell coating with mAb 6-10 days following mAb administration coincided with the appearance of anti-mouse Ig antibodies. Monkeys chronically infected with SIVmac that received a mAb of irrelevant specificity for 9-25 days all showed a transient increase in SIVmac provirus in PBL as measured by a quantitative polymerase chain reaction technique. In contrast, infected monkeys with > 800 CD4 cells/ul treated with anti-CD4 mAb for 9 days demonstrated no change in SIVmac provirus. However, infected monkeys with < 800 CD4 cells/ul had marginal anti-mouse Ig responses and could be treated with anti-CD4 mAb for 12-25 days. The three 5A8-treated monkeys with < 800 CD4 cell/ul all exhibited 5-10 fold decreases in SIVmac provirus load over the treatment period. Thus, the passive administration of anti-CD4 mAb may exert a specific anti-viral effect in the AIDS virus-infected individual.

Keywords: Animal Antibodies, Monoclonal/ADMINISTRATION & DOSAGE/*THERAPEUTIC USE Antigens, CD4/*IMMUNOLOGY HIV/PHYSIOLOGY Macaca mulatta Polymerase Chain Reaction/METHODS Proviruses/ISOLATION & PURIF/PHYSIOLOGY Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/*PREVENTION & CONTROL *SIV/ISOLATION & PURIF/PHYSIOLOGY T-Lymphocyte Subsets/*IMMUNOLOGY/MICROBIOLOGY Virus Replication/DRUG EFFECTS ABSTRACT
940730
M9470888

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .